Navigation Links
Pharmsynthez Reports Full Year 2012 Results in line US GAAP Financial Reporting
Date:7/17/2013

ST. PETERSBURG, Russia, July 17, 2013 /PRNewswire/ --

OJSC Pharmsynthez (Leningrad region, MICEX: LIFE) ("Pharmsynthez" or "the Company"), the leading Russian biopharmaceutical company that specializes in the development, manufacture and distribution of pharmaceuticals, has today published its consolidated audited results for the full year period ending 31 December 2012, in line with US GAAP. The results were compiled by leading global auditor, Ernst & Young.

Highlights

  • Consolidated sales of $8.5million (2011: $6.7 mln.)
  • Revenue of $12.7million in 2012 inclusive of Government co-financing of R&D
  • Consolidated gross profit $4.7million (2011: $3.7million)
  • Stable gross margin at 55%
  • EBITDA loss of $0.4million (2011: $0.4million) due to the strategic goal to increase R&D expenditures, exceeding the amount of Government co-financing
  • Virexxa Phase II clinical trial planned to begin in the US and EU in the third quarter of 2013
  • Myeloxen Phase IIa clinical research ongoing with results expected in the fourth quarter
  • Pulmoxen Phase I trial to begin during the third quarter

Dmitry Genkin, Chairman of Pharmsynthez, commented, "These positive operating indicators, including the growth in revenue, were achieved mainly thanks to the successive realization of plans to expand into the pharmaceutical markets of the Former Soviet Union and wider international markets. This has been key strategic objective of the Board and we are confident this will help deliver further growth and value for shareholders."

Notes to Editors

Pharmsynthez is a leading Russian pharmaceutical company focused on research, manufacture and distribution of active pharmaceutical ingredients (APIs), including those intended for import substitution.  Pharmsynthez also produces medicines (Neovir, Segidrin, Fenasid and Penkrofton) used in oncology, gynecology, treatment of immunodeficiencies and tuberculosis.

Financial Review

The growth in consolidated revenue from operations in 2012, as noted above, amounted to $1.8 million, up 27% from 2011. Sales by volume in the Russian Federation increased 6%, while in Ukraine they grew 3.2 times and 1.9 times in Estonia. Together with income from fulfilling R&D contracts financed by the Russian Ministry of Industry and Trade, the Company's revenue totaled $12.7 million.

Consolidated gross profit for 2012 amounted to $4.7 million, up 26% or $1 million from 2011. Meanwhile the gross margin remained almost unchanged at 55%.

In total for 2012 the Company posted a total of $88,000 of comprehensive income in total, versus a loss of $1.2million the previous year.

Pharmsynthez's commercial and management expenses grew 21% from the previous year and amounted to $4.8 million mainly due to salary expenses growth. Furthermore, the Company boosted its operational effectiveness by reducing the share of management expenses in revenue from 36% to 34%.

For 2012 the Company posted a $0.4 million loss on EBITDA versus a $0.4 million profit last year. The main reason for the decline in this indicator was reduced Government co-financing on R&D carried out under contracts with Russia's Ministry of Industry and Trade. In 2012 R&D expenditures significantly exceeded the amount of government co-financing as a result of the company's plans for independent development going forward.

The effect of other operating income in 2012 was minimal compared to 2011, when the Company posted $0.9 million in income from the revaluation of a land plot. Meanwhile, other operating expenses significantly increased to $0.9 million, and their main components, according to the rules for US GAAP in 2012 were $0.3 million in losses from FOREX changes, $0.1 million from property taxes, and $0.3 million from provision allocations.

The Company's shareholder capital corresponding to its consolidated balance increased in 2012 by $2 million to $22.5 million. It should also be noted that in 2012 Pharmsynthez issued 2,605,067 ordinary shares at a nominal price of five rubles per share ($0.16 at 31.12.2012 exchange rate). Furthermore, 2,605,000 shares were swapped with Sympatica Pharmaceuticals Limited for a 100% stake in LifeBio Laboratories Limited. 67 shares were acquired by third parties.

At its Annual General Meeting of shareholders in June, the Company confirmed Ernst & Young as the auditor for OJSC Pharmsynthez for 2013. Pharmsynthez publishes US GAAP accounts to increase operational transparency.

Clinical Review

The Company continued its intensive work towards developing innovative products for its own portfolio and developing the Company's production base. As a result, the Company was able to make significant progress on its key projects.

Virexxa, for the treatment of endometrial cancer: Production of Virexxa has been organized in compliance with European cGMP standards. As requested by the FDA additional research was performed on the drug's safety and action mechanism. Phase II clinical research for the drug was completed for patients with advanced and recurrent endometrial cancer in the Russian Federation. Phase II clinical research in the US and EU is planned for the third quarter of 2013.

Myeloxen, for the treatment of multiple sclerosis: A Phase IIa study of Myeloxen is ongoing in the Russian Federation with results of this study expected in the fourth quarter. The Company has focused on ensuring that Myeloxen is produced to the highest standards and production of Myeloxen is in compliance with European cGMP standards. New and unique production capacity has been developed and launched for this product, including a module for automated high-production solid-phase synthesis and ultra-fine peptide peelings, as well as a production module for nano-encapsulation and manufacturing in liposomal form, thereby ensuring the highest technological level of capacity.

Pulmoxen, for the treatment of cystic fibrosis: Pre-clinical research has been completed and a unique high-production eukaryotic strain was created for the producer of a fused protein dornase alfa. Production of the drug has been organized in compliance with cGMP standards. A unique production model has been created and launched having an automated highly effective chemical synthesis based on circulating Q-Mix micro-reactors. The start of Phase I study for Pulmoxen will begin in the third quarter of 2013.  

Contact for Investors and Journalists:
Russia: Tom Blackwell. International: Amber Bielecka / Matthew Neal
T: +44(0)20-7920-2333
T: +7-495-663-8009
pharmsynthez@mcomgoup.com


'/>"/>
SOURCE Pharmsynthez
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... ... 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the ... ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength ... , Removal of the homeopathic element , Adding their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to May ... Medicine will host industry leaders for the annual spring Convention & Expo, called ... industry adapt to the issues currently affecting urgent care and on-demand healthcare. , ...
Breaking Medicine News(10 mins):